SCHEMBL23747981

SCHEMBL23747981

COc1ccc(CNc2nc(NCCO)c3ccccc3n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.66
MERTK Q12866 3/20 0.65
RAD52 P43351 6/20 0.65
APP P05067 4/20 0.65
KMT2A Q03164 2/20 0.64
POLB P06746 2/20 0.64
HTT P42858 3/20 0.63
KDM4E B2RXH2 2/20 0.63
TAAR1 Q96RJ0 2/20 0.63
USP2 O75604 1/20 0.60
TSHR P16473 1/20 0.60
CASP6 P55212 1/20 0.59
ALDH1A1 P00352 1/20 0.58
LMNA P02545 1/20 0.58
MAPT P10636 1/20 0.58
PKM P14618 1/20 0.58
UBE2N P61088 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
RCE1 Q9Y256 1/20 0.58
BCHE P06276 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23747941 0.91 ACHE (0.63) MERTKRAD52APPKMT2APOLB
SCHEMBL2255109 0.89 SLC2A1 (0.81) SLC2A1RAD52APPKMT2APOLB
SCHEMBL2586993 0.89 SLC2A1 (0.81) SLC2A1RAD52APPKMT2APOLB
Hydrochloric Acid SCHEMBL3640013 0.88 SLC2A1 (0.80) SLC2A1RAD52APPKMT2APOLB
SCHEMBL23747980 0.87 HTT (0.72) SLC2A1MERTKRAD52APPKMT2A
SCHEMBL30125191 0.87 HTT (0.72) SLC2A1MERTKRAD52APPKMT2A
SCHEMBL23748460 0.87 RAD52 (0.77) RAD52APPKMT2APOLBHTT
SCHEMBL26646013 0.86 MERTK (0.87) SLC2A1MERTKRAD52KMT2APOLB
SCHEMBL3106463 0.85 CCNE2 (0.58) SLC2A1MERTKRAD52APPKMT2A
SCHEMBL3117720 0.84 BCHE (0.78) SLC2A1MERTKRAD52APPKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2023-10-26 US disclosed
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2023-10-26 US disclosed
EP-4100395-A1 QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER Trobio Therapeutics Pty Ltd (AU) 2022-12-14 EP disclosed
WO-2021155426-A1 QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339866-A1 Quinazoline compounds and the use thereof in the treatment of cancer NQO2, TP53, ABL1 SLC2A1 3899/4885MERTK 1336/4885RAD52 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.